^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD1390

    i
    Company:
    AstraZeneca
    Drug class:
    ATM kinase inhibitor
    Related drugs:
    Apply
    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer (NCT03423628)
    Phase 1
    AstraZeneca
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    04/02/2018
    Primary completion :
    04/22/2026
    Completion :
    04/22/2026
    IDH1
    |
    IDH1 mutation
    |
    AZD1390